The Drug That Cracked Biotech's Most Cursed Target
For 20 years, every attempt to turn myostatin inhibitors into real drugs ended in failure. Scholar Rock just broke the curse with the first FDA-approved muscle-targeted therapy for spinal muscular atrophy, and the implications stretch far beyond rare disease.
For two decades, myostatin inhibitors were biotech's version of a broken promise. Drug after drug showed it could build muscle in the lab, only to flop in patients. Pfizer tried. Lilly tried. Regeneron tried. The graveyard was so full that targeting myostatin became almost a punchline at industry conferences, the biotech equivalent of "this time it'll be different" right before it wasn't.
Then Scholar Rock actually did it.
A First That Almost Nobody Expected
The FDA approved ISEMBYLD (apitegromab) for the treatment of spinal muscular atrophy (SMA), a rare genetic disease that causes progressive muscle weakness and the loss of nerve cells controlling movement. The approval covers adults and children aged two and older who are already receiving a gene-targeted SMA therapy.
This is Scholar Rock's first-ever FDA approval, and it's a milestone that extends far beyond one company. ISEMBYLD is the first muscle-targeted treatment for SMA, a disease that affects roughly 10,000 children and adults in the U.S. alone. Existing therapies like nusinersen and risdiplam attack the genetic root cause of SMA, but they don't directly address the muscle weakness that patients still live with every day. Think of it like fixing a car's engine without repairing the worn-out tires: the vehicle runs, but it still doesn't drive right.
ISEMBYLD is meant to be the tire repair. It's designed as an add-on, not a replacement, layered on top of existing treatments to target the muscle side of the equation.
The Graveyard Scholar Rock Had to Walk Through
To appreciate what happened here, you need to understand how many companies have failed at this exact thing.
Myostatin is a protein that acts like a brake on muscle growth. Block it, and muscles should get bigger and stronger. That logic is solid in mice. In humans? Not so much. The field's first clinical attempt, Pfizer's stamulumab, fizzled out after showing limited benefit. Later came domagrozumab (also Pfizer), Lilly's LY2495655, and a parade of other molecules with alphabet-soup names. Some increased lean muscle mass on a scan but couldn't translate that into patients actually moving better or feeling stronger.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The pattern was brutal and consistent: muscles got bigger on paper, but function didn't follow. Reviews of the field have pointed to a recurring gap between preclinical promise and clinical reality, especially in complex diseases where muscle mass alone doesn't determine disability. By the mid-2020s, most investors had mentally filed myostatin inhibitors under "great idea, doesn't work."
So what made Scholar Rock different?
A Smarter Way to Hit the Target
Most previous myostatin inhibitors tried to block the protein after it was already active and circulating in the body. Scholar Rock took an upstream approach. Their antibody, apitegromab, binds to pro-myostatin and latent myostatin (the precursor forms) before they get activated in the first place.
If old myostatin blockers were like trying to catch a ball mid-flight, Scholar Rock's approach was more like keeping the pitcher from throwing it. By intercepting the pathway earlier, the company bet it could achieve a cleaner, more selective blockade.
The other key decision was disease selection. Instead of chasing broad conditions like sarcopenia (age-related muscle loss), where the biology is messy and endpoints are hard to measure, Scholar Rock focused on SMA patients already on gene-targeted therapy. That gave them a well-defined population with standardized motor function tests and a clear rationale: these patients had their genetics partially fixed but still needed help rebuilding muscle.
The Trial That Proved It
The pivotal Phase 3 SAPPHIRE trial enrolled children and adults with SMA (types 2 and 3) aged 2 to 21, all of whom were on background therapy with nusinersen or risdiplam.
The primary endpoint was improvement on the Hammersmith Functional Motor Scale-Expanded (HFMSE), a standardized test that measures things like sitting, standing, and limb movement. At the recommended dose, patients on apitegromab showed a 2.2-point improvement over placebo, hitting statistical significance with a p-value of 0.0121.
That number might sound modest if you're used to blockbuster cancer data. But in SMA, where motor function gains are painstakingly slow, it's meaningful. For context, 30% of treated patients achieved a 3-point or greater improvement on the scale, compared to just 12.5% on placebo. That's nearly two-and-a-half times the response rate, which in a rare disease with limited options, matters enormously to families.
From Lab Bench to Launch Pad
Scholar Rock's journey started in 2012 at Harvard Medical School and Boston Children's Hospital. The company was built on discoveries by Timothy A. Springer and Leonard I. Zon around the TGF-beta superfamily, a group of signaling proteins involved in growth and tissue regulation. It went public on Nasdaq in 2018 and spent years advancing apitegromab through clinical development.
The stock has been volatile around the approval. Shares traded around $42 in early October 2026. Analysts still see room to run: the consensus price target sits at roughly $67.67, implying significant upside from current levels. The stock carries a "Moderate Buy" rating, suggesting Wall Street views the commercial opportunity as real but wants to see the launch unfold.
The company hasn't publicly detailed its pricing or commercialization strategy (at least not in available disclosures), which leaves a key question unanswered: how aggressively will Scholar Rock price a rare disease therapy that's used alongside, not instead of, treatments that already cost six figures annually?
Why This Matters Beyond SMA
Scholar Rock isn't done with myostatin. The company is running the EMBRAZE trial, testing apitegromab in obesity and overweight patients on GLP-1 drugs (like Ozempic or Mounjaro) to see if it can preserve lean muscle mass during weight loss. If that works, the commercial opportunity dwarfs SMA.
But that's tomorrow's story. Today's story is simpler and, honestly, more satisfying.
For 20 years, the best minds in biotech couldn't make a myostatin inhibitor work in the clinic. Scholar Rock, a mid-size company from Cambridge with a clever antibody and a smarter trial design, just proved it could be done. SMA patients now have a treatment option that no one else could deliver.
Sometimes the most important breakthroughs aren't the flashiest ones. They're the ones everyone else gave up on.
4 min read
GSK Thinks It Can Build a Better Flu Shot With mRNA
GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.
